ShedRX
GLP-1 weight-loss telehealth with the lowest entry price in the category - compounded Semaglutide and Tirzepatide from $199/mo, plus needle-free sublingual drops and lozenges for buyers who want to skip injections.
Compounded Semaglutide and Tirzepatide from $199/mo - the lowest entry price among the credible GLP-1 telehealth platforms - plus sublingual drops and lozenges for buyers who want the same class of medication without weekly injections. Same active molecules as Wegovy, Ozempic, Mounjaro, and Zepbound, prescribed online if you medically qualify.
ShedRX entered the GLP-1 telehealth segment with two differentiators against the rest of the category: the lowest published entry price ($199/mo for compounded Semaglutide or Tirzepatide vs $249-349/mo at most competitors), and needle-free formats - sublingual drops and dissolvable lozenges - for buyers who want the same class of medication without weekly self-injection.
The medication itself is the same active-molecule story as the rest of the segment. Semaglutide is the active in Wegovy and Ozempic; Tirzepatide is the active in Zepbound and Mounjaro. ShedRX sources these through compounding-pharmacy partnerships under 503A patient-specific compounding rather than branded retail. The clinical effect of the molecule is the same; what differs is sourcing, price, and - importantly - regulatory standing. Compounded GLP-1 is prepared by licensed pharmacies from active ingredients sourced from FDA-registered facilities, but the finished compounded product is not itself FDA-reviewed or approved the way branded Wegovy or Zepbound is. That is the trade buyers are making for the lower price.
For longevity buyers, GLP-1 occupies the same narrow-but-growing segment it does across the category: metabolic-health work where weight is a meaningful lever and diet plus training alone hasn't closed the gap. The 2024-2026 research has moved GLP-1s from pure weight-loss into metabolic-aging territory, with cardiovascular, inflammatory, and cognitive signals documented across multiple trials.
The needle-free angle deserves an honest note: sublingual drops and lozenges trade injection avoidance for less predictable absorption than subcutaneous injection, where dosing is well-characterized. For buyers who would not start GLP-1 at all because of needle aversion, the needle-free tier lowers the barrier; for buyers optimizing for proven dose-response, the injectable tier remains the reference standard.
The competitive frame: ShedRX sits alongside bmiMD, Hims, Henry Meds, and Levity in compounded GLP-1 telehealth. Its edge is entry price and format choice; bmiMD's edge is MD-oversight framing and titration structure. The honest take - if you want GLP-1 access at the lowest monthly cost, or you specifically want a needle-free option, ShedRX is one of the strongest picks in the category. If you want the most-studied delivery and structured clinical oversight, compare it directly against bmiMD before deciding.
Buyers who want GLP-1 access at the lowest telehealth entry price, or who specifically want a needle-free format (sublingual drops or dissolvable lozenges) instead of weekly injections.
You have not yet tried diet, training, and lab work - start there first. Or you have insurance that covers branded Wegovy / Zepbound (run those through your own physician instead). Compounded GLP-1 is also in a shifting FDA and state-regulatory environment, so confirm current availability and rules in your state before subscribing.
Specifications
Most often compared with
Where this fits
ShedRX GLP-1 Telehealth (Semaglutide / Tirzepatide + Needle-Free) cross-shops across several editorial surfaces - the full brand catalog, the buyer-intent tags this item carries, the price band it qualifies for, and any execution playbook that uses it.
ShedRX GLP-1 Telehealth (Semaglutide / Tirzepatide + Needle-Free) - buyer FAQ
Is ShedRX compounded Semaglutide the same as Wegovy or Ozempic?
The active ingredient is identical - Semaglutide. The difference is the manufacturer: Wegovy and Ozempic are produced by Novo Nordisk under brand-name FDA approval; ShedRX's version is produced by US-licensed compounding pharmacies under 503A patient-specific compounding rules. Same molecule, same mechanism. The finished compounded product is not separately FDA-reviewed the way branded Wegovy is - that regulatory difference is the trade for the lower price.
What are the needle-free options and do they work as well as injections?
ShedRX offers sublingual drops (from $229/mo) and dissolvable lozenges (from $199/mo) in addition to weekly injections. They use the same active class, but absorption through the sublingual/oral route is less precisely characterized than subcutaneous injection, where dose-response is well-studied. For needle-averse buyers, the needle-free tier lowers the barrier to starting at all; for buyers optimizing for proven dosing, the injectable tier remains the reference standard.
How much does ShedRX cost vs branded Wegovy or Zepbound?
ShedRX: compounded Semaglutide and Tirzepatide from $199/mo, drops from $229/mo. Branded without insurance: Wegovy/Ozempic $1,400-1,800/mo, Zepbound/Mounjaro $1,500-1,800/mo. Branded WITH insurance: often a $25-100 co-pay. Note ShedRX charges a $99 platform fee only on branded Wegovy/Zepbound, not on the compounded tiers. For uninsured buyers, the compounded route is multiples cheaper than brand.
Do I need a prescription before signing up with ShedRX?
No. The flow includes the consult that produces the prescription - an online questionnaire plus review by a US-licensed clinician. The prescription is issued during onboarding if you medically qualify. You do not bring an existing prescription; you go through the ShedRX clinician.
ShedRX vs bmiMD - how do I choose?
Both are compounded GLP-1 telehealth platforms. ShedRX leads on entry price (from $199/mo) and format choice (injection plus needle-free drops and lozenges). bmiMD leads on MD-oversight framing and structured titration support, at roughly $249-349/mo. If lowest monthly cost or a needle-free option matters most, ShedRX; if structured clinical oversight matters most, bmiMD. Either way, confirm the platform covers your state before paying.